[Essence of the Japan Atherosclerosis Society (JAS) Guidelines for the Diagnosis and Prevention of Atherosclerotic Cardiovascular Diseases in Japan-2012 Version and Treatment Guide for Dyslipidemia 2013--Current Strategy for the Lipid Assessment].
Dyslipidemia is one of the most important risk factors for atherosclerotic cardiovascular diseases (ASCVD), and its management is very important for the prevention of ASCVD. In addition, the management of other major risk factors, such as cigarette smoking, hypertension, and diabetes, is also important. Therefore, the comprehensive management of these major risk factors is key to prevent ASCVD. Among several types of primary dyslipidemia, familial hypercholesterolemia (FH) is a very high-risk genetic disorder which causes premature coronary artery disease (CAD). Therefore, the early diagnosis of and treatment for FH are crucial. For the treatment of dyslipidemia, lifestyle modifications are the bases of ASCVD prevention. However, when lipid management goals are not achieved with lifestyle modification, we should consider pharmacological treatments, and statins are the drugs with the most abundant evidence to support LDL-C-lowering and ASCVD prevention.